Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Official title: A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2025-03-31
Completion Date
2027-09-17
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
Biological/Vaccine
Infused into the hepatic portal vein.
Locations (7)
Perelman Center for Advanced Medicine - Endocrinology
Philadelphia, Pennsylvania, United States
Montefiore Clinical and Translational Research Center - Endocrinology
Pittsburgh, Pennsylvania, United States
UW University Hospital - Endocrinology
Madison, Wisconsin, United States
Toronto General Hospital - Endocrinology
Toronto, Canada
Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre
Vancouver, Canada
King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology
Riyadh, Saudi Arabia
King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology
Riyadh, Saudi Arabia